Article
Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity.
Nature - 1 Mar 2022
Meng Bo, Abdullahi Adam, Ferreira Isabella A T M, Goonawardane Niluka, Saito Akatsuki, Kimura Izumi, Yamasoba Daichi, Gerber Pehuén Pereyra, Fatihi Saman, Rathore Surabhi, Zepeda Samantha K, Papa Guido, Kemp Steven A, Ikeda Terumasa, Toyoda Mako, Tan Toong Seng, Kuramochi Jin, Mitsunaga Shigeki, Ueno Takamasa, Shirakawa Kotaro, Takaori-Kondo Akifumi, Brevini Teresa, Mallery Donna L, Charles Oscar J, Bowen John E, Joshi Anshu, Walls Alexandra C, Jackson Laurelle, Martin Darren, Smith Kenneth G C, Bradley John, Briggs John A G, Choi Jinwook, Madissoon Elo, Meyer Kerstin B, Mlcochova Petra, Ceron-Gutierrez Lourdes, Doffinger Rainer, Teichmann Sarah A, Fisher Andrew J, Pizzuto Matteo S, de Marco Anna, Corti Davide, Hosmillo Myra, Lee Joo Hyeon, James Leo C, Thukral Lipi, Veesler David, Sigal Alex, Sampaziotis Fotios, Goodfellow Ian G, Matheson Nicholas J, Sato Kei, Gupta Ravindra K
Abstract excerpt
The SARS-CoV-2 Omicron BA.1 variant emerged in 20211 and has multiple mutations in its spike protein2. Here we show that the spike protein of Omicron has a higher affinity for ACE2 compared with Delta, and a marked change in its antigenicity increases Omicron's evasion of therapeutic monoclonal and vaccine-elicited polyclonal neutralizing antibodies after two doses. mRNA vaccination as a third vaccine dose...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.